Evidence map›Paper›PMID 37762005›Full record

ArticleInternational journal of molecular sciences2023

The TGF-β/UCHL5/Smad2 Axis Contributes to the Pathogenesis of Placenta Accreta.

Kei Hashimoto, Yuko Miyagawa, Saya Watanabe, Kazuki Takasaki, Miki Nishizawa, Keita Yatsuki, Yuko Takahashi, Hideo Kamata, Chikara Kihira, Haruko Hiraike and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Kei HashimotoDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Yuko MiyagawaDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Saya WatanabeDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Kazuki TakasakiDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Miki NishizawaDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Keita YatsukiDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Yuko TakahashiDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Hideo KamataDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.ORCID 0000-0003-3471-0994
Chikara KihiraDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Haruko HiraikeDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Yukifumi SasamoriDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Koichiro KidoDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Eiji RyoDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
Kazunori NagasakaDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.ORCID 0000-0002-0696-5175
Teikyo University · JP

Funding

Ministry of Education, Science and Culture, Japan 19K09834, 22K09554
6 · The paper itself

Abstract

Placenta accreta is a high-risk condition causing obstetric crisis and hemorrhage; however, its pathogenesis remains unknown. We aimed to identify the factors contributing to trophoblast invasiveness and angiogenic potential, which in turn drive the pathogenesis of placenta accreta. We focused on the transforming growth factor (TGF)-β1-Smad pathway and investigated the intrinsic relationship between the time- and dose-dependent inhibition of the ubiquitinating enzyme UCHL5 using bAP15, a deubiquitinase inhibitor, after TGF-β1 stimulation and the invasive and angiogenic potential of two cell lines, gestational choriocarcinoma cell line JEG-3 and trophoblast cell line HTR-8/SVneo. UCHL5 inhibition negatively regulated TGF-β1-induced Smad2 activation, decreasing extravillous trophoblast invasiveness. Smad1/5/9 and extracellular signal-regulated kinase (ERK) were simultaneously activated, and vascular endothelial growth factor was secreted into the trophoblast medium. However, extravillous trophoblast culture supernatant severely impaired the vasculogenic potential of human umbilical vein endothelial cells. These results suggest that the downstream ERK pathway and Smad1/5/9 potentially regulate the TGF-β1-Smad pathway in extravillous trophoblasts, whereas Smad2 contributes to their invasiveness. The abnormal invasive and angiogenic capacities of extravillous cells, likely driven by the interaction between TGF-β1-Smad and ERK pathways, underlie the pathogenesis of placenta accreta.

Indexed as

Cysteine ProteasesPlacenta AccretaCell Line, TumorExtracellular Signal-Regulated MAP KinasesFemaleHumansHuman Umbilical Vein Endothelial CellsPregnancyTransforming Growth Factor betaTransforming Growth Factor beta1Ubiquitin ThiolesteraseVascular Endothelial Growth Factor ACysteine ProteasesExtracellular Signal-Regulated MAP KinasesTransforming Growth Factor betaTransforming Growth Factor beta1Ubiquitin ThiolesteraseUCHL5 protein, humanVascular Endothelial Growth Factor Aangiogenesiscell invasionextracellular signal-regulated kinaseplacenta accreta spectrumplacentogenesis trophoblastSmad

Identifiers

PMID37762005
PMCPMC10530686
OpenAlexW4386443877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.